Aratana Therapeutics Inc. (NASDAQ:PETX) saw unusually-high trading volume on Tuesday . Approximately 1,203,807 shares traded hands during mid-day trading, an increase of 24% from the previous session’s volume of 972,851 shares.The stock last traded at $9.02 and had previously closed at $9.41.

PETX has been the topic of several research reports. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Wednesday, July 20th. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research report on Tuesday, April 26th. Barclays PLC lowered their price objective on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $11.00 price objective on shares of Aratana Therapeutics in a research report on Wednesday, August 10th. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Aratana Therapeutics in a research report on Sunday, July 17th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $11.16.

The company has a 50-day moving average price of $7.31 and a 200-day moving average price of $5.87. The firm’s market cap is $318.03 million.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.24 by $0.37. During the same period in the prior year, the business posted ($0.23) EPS. The company earned $38.05 million during the quarter, compared to analyst estimates of $15.14 million. Equities analysts anticipate that Aratana Therapeutics Inc. will post ($0.73) earnings per share for the current year.

In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total transaction of $462,500.00. Following the completion of the sale, the insider now owns 642,793 shares of the company’s stock, valued at $5,945,835.25. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ernst Heinen sold 15,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $6.72, for a total value of $100,800.00. Following the sale, the insider now directly owns 125,494 shares of the company’s stock, valued at approximately $843,319.68. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.